Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xermelo and Lutathera in neuroendocrine tumors
NCT04543955Phase 2Terminated
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telotristat ethyl in Neuroendocrine Neoplasm (NEN) (2 arms). Primary endpoint: Progression-Free Survival at 20 months. Started Sep 2021; status: terminated.
02
Drugs
telotristat ethyl
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04543955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543955.